Avid Bioservices Inc (CDMO)

[cjgaddy]

SK 12-15-15/BioWorld on AZN: “We save probably as much as we're spending because of the cost of these drugs.”

12-15-15/BioWorld: “If You Can't Beat 'em, Join 'em; Looking for Immuno-onc Boost”
By Brian Orelli, BioWorld Staff Writer
...
Earlier this year, Peregrine partnered up with Astrazeneca to test the pharma's anti-PD-L1 immune checkpoint inhibitor, durvalumab, with bavituximab, after preclinical data suggested that the combination might help even if tumors don't initially express PD-L1. By removing the phosphatidylserine checkpoint, the immune system is activated, but the tumor can then use PD-L1 to inhibit the immune system. Durvalumab should help perpetuate the bavituximab-induced immune response, while boosting the opportunity for durvalumab in tumors that are not expressing PD-L1 until the bavituximab treatment. "It's sort of a win-win situation," King said. ...

King said he thinks that bavituximab will likely work with any of the drugs targeting the PD-1 pathway, but decided to work with London-based Astrazeneca rather than one of the FDA-approved drugs, in part, because Astrazeneca was willing to provide the drug free of charge. "We save probably as much as we're spending because of the cost of these drugs," King said.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119200003